These strategies all failed to achieve statistically significant reduction in the 28-day mortality rate of septic shock patients in phase III clinical trials (2).
Activated protein C (APC; Xigris), a natural anticoagulant protein, exhibited effectiveness in severe sepsis patients (3) and has been approved by the FDA as an antisepsis drug.